The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

Category: Pharma & Human Health

Lactobacillus manipulates bile acids to create favorable gut environment
Biotics and Supplements

Lactobacillus manipulates bile acids to create favorable gut environment

FEB 4, 2021
Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132
Clinical & Manufacturing

Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132

FEB 3, 2021
Study suggests that gut fungi are not associated with Parkinson’s disease
Gut-Brain Axis

Study suggests that gut fungi are not associated with Parkinson’s disease

FEB 1, 2021
Why microbiota samples should be collected in all clinical trials?
Clinical & Manufacturing

Why microbiota samples should be collected in all clinical trials?

JAN 26, 2021
Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19
Editor's Choice

Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19

JAN 20, 2021
Felix Biotechnology announces initiation of a Phase 1/2 study at Yale for targeted phage therapy in the treatment of P. aeruginosa infections
Clinical & Manufacturing

Felix Biotechnology announces initiation of a Phase 1/2 study at Yale for targeted phage therapy in the treatment of P. aeruginosa infections

JAN 20, 2021
Poor gut health connected to severe COVID-19, new review shows
Editor's Choice

Poor gut health connected to severe COVID-19, new review shows

JAN 18, 2021
Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
Finance

Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.

JAN 13, 2021
Landmark human study is first to reveal strong links between specific gut microbes, diet and health, including weight
Pharma & Human Health

Landmark human study is first to reveal strong links between specific gut microbes, diet and health, including weight

JAN 12, 2021
Eligo inks deal with GSK potentially worth up to $224M
Finance

Eligo inks deal with GSK potentially worth up to $224M

JAN 12, 2021
The incredible, variable bacteria living in your mouth
Biotics and Supplements

The incredible, variable bacteria living in your mouth

JAN 8, 2021